Returns on Pharma R&D still declining; report

14 December 2017

Projected returns on investment in research and development (R&D) for the top 12 pharmaceutical companies has fallen to just 3.2% this year, down from 10.1% in 2010, according to an annual study by Deloitte’s Centre for Health Solutions.

The average cost for these companies to bring a drug to market has increased to record levels of just under $2 billion, up from $1,188 million in 2010 and $1,539 million in 2016. Conversely, forecast peak sales per asset – the amount of money a drug is expected to generate annually – has remained well below the 2010 value of $816 million, to reach only $465 million in 2017, albeit this is an increase from $394 million in 2016.

The full report can be viewed here.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK